U.S. Markets closed

AtriCure Inc (ATRC) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

AtriCure Inc (ATRC) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. AtriCure Inc is a medical device company. It develops, manufactures and sells cardiac surgical ablation systems designed to create precise lesions, scars in cardiac, heart, and tissue. It generates revenue by selling disposable surgical devices. AtriCure Inc has a market cap of $1.19 billion; its shares were traded at around $30.77 with and P/S ratio of 5.23.

For the last quarter AtriCure Inc reported a revenue of $49.9 million, compared with the revenue of $42.15 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $201.6 million, an increase of 15.4% from last year. For the last five years AtriCure Inc had an average revenue growth rate of 19.2% a year.

The reported loss per diluted share was 62 cents for the year, compared with the loss per share of $0.61 in the previous year. The AtriCure Inc had an operating margin of -8.49%, compared with the operating margin of -14.3% a year before. The 10-year historical median operating margin of AtriCure Inc is -14.77%. The profitability rank of the company is 5 (out of 10).

At the current stock price of $30.77, AtriCure Inc is traded at 66.6% premium to its historical median P/S valuation band of $18.47. The P/S ratio of the stock is 5.23, while the historical median P/S ratio is 3.14. The stock gained 73.74% during the past 12 months.

For the complete 20-year historical financial data of ATRC, click here.

This article first appeared on GuruFocus.